Free Trial

Should Procter and Gamble be a Staple in Your Portfolio?

→ The World's First "$20 Trillion Drug?" (From Behind the Markets) (Ad)

Key Points

  • P&G sells consumer staples brands like Tide, Pampers, Bounty to over 170 countries  
  • Consumer staples are the defensive play in weakening economic climates hampered by high inflation 
  • The strong U.S. dollar is having a $400 million incremental hit for full-year estimates
  • P&G offsets rising inflation by raising prices and passing it directly to customers  
  • Its portfolio of daily use products from cleaning to hygiene will drive organic sales growth of 3% to 5% for the new fiscal year
  • Shares trade at 22X forward earnings with a 2.84% annual dividend yield
  • 5 stocks we like better than Procter & Gamble

Should Proctor and Gamble be a Staple in Your Portfolio? The world’s largest consumer goods maker Procter & Gamble NYSE: PG stock has fallen (-21%) for the year. Shares hit pandemic highs of $146.92 in November 2020 as consumers stockpiled its products before falling back down to $121.54 post-pandemic lows in March 2021. Ironically, post-pandemic frenzied buying drove shares up to a new high of $165.35 in January 2022 and it hasn’t looked back as it sold off to $122.18 lows. The maker of 65 popular household brands including Tide, Gain, Febreze, Mr. Clean, Oral-B, Crest, Bounty and Pampers distributes its products to over 170 countries. Recession fears tend to drive investors into defensive plays in the consumer staples sector with consistent dividend payouts. P&G is comprised of 10 product divisions ranging from Personal , Fabric, Home, Baby, Beauty, Hair, Skin and Grooming Care. Its largest customer is Walmart NYSE: WMT. The Company has faced normalization after tough comparables last year.

Mitigating Inflation

Price hikes and operational efficiencies helped P&G mitigate some inflationary headwinds to improve its profit margins. Unfavorable foreign exchange took a (-6%) toll on net sales. The decline in the Russian market took a (-2%) to (-3%) decline in organic sales. Like consumer staples peers Clorox NYSE: CLX, Unilever NYSE: UL, Church & Dwight NYSE: CHD and Colgate-Palmolive NYSE: CL, P&G also faces competition from generic and private label brands which consumers are flocking to. The Company plans to raise prices again in feminine, U.S. home and U.S. oral care products. The Company is growing organic sales in all 10 product categories. The U.S. saw a 5% rise in sales while China saw organic sales fall (-4%) due to COVID restrictions and lockdowns.


Beating Estimates Despite Headwinds

On Oct. 19, 2022, P&G released its fiscal first-quarter 2023 results for the quarter ending October 2022. The Company reported a profit of $1.57 per share beating consensus analyst estimates for $1.55 per share by $0.02. Revenues rose 1.3% year-over-year (YoY) to $20.61 billion beating consensus analyst estimates for $20.37 billion. P&G CEO Jon Moeller commented, “These results enable us to maintain our guidance ranges for organic sales and EPS growth for the fiscal year despite continued significant headwinds. We remain committed to our integrated strategies of a focused product portfolio, superiority, productivity, constructive disruption and an agile and accountable organization structure. These strategies have enabled us to build and sustain strong momentum. They remain the right strategies to navigate through the near-term challenges we’re facing and continue to deliver balanced growth and value creation.”

Lower Fiscal 2023 Outlook

P&G issued downside guidance for full-year 2023 EPS between $5.81 to $6.04 versus $5.83 consensus analyst estimates. Revenue are expected to fall (-3%) to (-1%) or $77.8 billion to $79.4 billion versus $79.97 billion analyst estimates. P&G expects adjusted free cash flow productivity of 90% with a $9 billion in dividends and plans to buyback between $6 billion to $8 billion.  

Should Proctor and Gamble be a Staple in Your Portfolio?

Here’s What the Chart Says

Using the rifle charts on weekly and daily charts can provide a near-term perspective of the playing field for PG stock. The weekly rifle chart downtrend was triggered on the $130.09 Fibonacci (fib) level breakdown. The weekly downtrend is led by the falling 5-period moving average (MA) at $127.95 followed by the 15-period MA at $137.70. Shares fell through the weekly market structure low (MSL) buy trigger at $133.00 and weekly 200-period MA support at $127.95. The weekly lower Bollinger Bands (BBs) sit at $119.04. The weekly stochastic has fallen through the 20-band. The daily rifle chart has an uptrend with a rising 5-period MA followed by the 15-period MA support at $126.88. The daily stochastic formed a bullish mini pup as it rises through the 50-band. The daily 50-period MA at $136.11 nearly overlapping the daily upper BBs at $135.69. Attractive pullback levels sit at the $125.45 fib, $123.43, $122.18, $121.38 fib, $119.65 fib, $118.30 fib, and $115.59 fib level.

→ The World's First "$20 Trillion Drug?" (From Behind the Markets) (Ad)

Should you invest $1,000 in Procter & Gamble right now?

Before you consider Procter & Gamble, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Procter & Gamble wasn't on the list.

While Procter & Gamble currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Procter & Gamble (PG)
4.5296 of 5 stars
$162.550.0%2.48%26.56Moderate Buy$169.76
Walmart (WMT)
4.5345 of 5 stars
$60.21+0.6%1.38%31.47Moderate Buy$61.75
Clorox (CLX)
3.6057 of 5 stars
$147.51-0.2%3.25%234.15Reduce$148.63
Church & Dwight (CHD)
4.4431 of 5 stars
$107.25-0.1%1.05%35.28Hold$104.07
Unilever (UL)
1.4546 of 5 stars
$50.92+5.9%3.55%N/AReduce$48.00
Colgate-Palmolive (CL)
4.8345 of 5 stars
$89.27+0.5%2.24%32.11Moderate Buy$89.50
Compare These Stocks  Add These Stocks to My Watchlist 

Jea Yu

About Jea Yu

  • JeaYu21@gmail.com

Contributing Author

Trading Strategies

Experience

Jea Yu has been a contributing writer for MarketBeat since 2018.

Areas of Expertise

Equities, options, ETFs and futures; fundamental, qualitative, quantitative and technical analysis and pattern identification; active and swing trading; trading systems and methodology development

Education

Bachelor of Arts, University of Maryland, College Park

Past Experience

U.S. equity markets trader, writer and analyst for over 25 years. Published four books by publishers McGraw-Hill, John Wiley & Sons, Marketplace Books and Bloomberg Press. Speaker at various expos and seminars and has been quoted and featured in USA Today, The Wall Street Journal, Traders Magazine, The Financial Times and various trade publications, including Stocks & Commodities, Active Trader and Online Investor.


Featured Articles and Offers

How to Become a "Make Money" Investor

How to Become a "Make Money" Investor

Whether you're a seasoned investor or just starting, this video offers valuable insights into making strategic choices that prioritize long-term growth and stability over short-term gains.

Search Headlines: